Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.82 |
| ▸ | RARB | P10826 | 10/20 | 0.82 |
| ▸ | RARG | P13631 | 10/20 | 0.82 |
| ▸ | CYP26A1 | O43174 | 6/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | BLVRB | P30043 | 1/20 | 0.68 |
| ▸ | HNF4A | P41235 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8522186 | 0.91 | RARA (0.68) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL10541382 | 0.91 | RARB (0.69) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL726740 | 0.90 | RARB (1.00) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL29355626 | 0.90 | RARB (1.00) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL8776375 | 0.89 | RARA (0.65) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL8459704 | 0.87 | RARA (0.80) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL9446527 | 0.87 | CYP26A1 (0.80) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL1616078 | 0.86 | CYP26A1 (0.78) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL9446600 | 0.86 | RARA (0.78) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL1616121 | 0.86 | CYP26A1 (0.78) | RARARARBRARGCYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0410358-A1 | Aromatic carboxylic acid amides, their preparation and their use as medicines | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-30 | — | — | EP | claimed |
| US-6476017-B2 | (DIBENZO(B,E)(1,4)-DIAZEPINE-11-YL)BENZOIC ACID DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-0906907-B1 | COMPOUNDS POTENTIATING RETINOID | INST MED MOLECULAR DESIGN INC (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-20010039272-A1 | Compounds activating pharmacological effect of retinoids | KEMPHYS LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6121256-A | 4-(2,3-(2,5-DIMETHYL-2,5-HEXANO)DIBENZO(B,F)(1,4)THIAZEPINE-11 -YL)BENZOIC ACID OR SALT | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2000-09-19 | — | — | US | disclosed |
| WO-1999048529-A1 | RETINOID-GLITAZONE COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-30 | — | — | WO | disclosed |
| US-5929069-A | CARBOXYPHENYL-SUBSTITUTED DIBENZO(B,F)(1,4)DIAZEPINE DERIVATIVES; TREATMENT OF VITAMIN A DEFICIENCY DISEASES, SKIN DISORDERS, LEUKEMIA | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 1999-07-27 | — | — | US | disclosed |
| EP-0906907-A1 | COMPOUNDS POTENTIATING RETINOID | Institute of Medicinal Molecular Design, Inc. (JP) | 1999-04-07 | — | — | EP | disclosed |
| EP-0808159-A1 | USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024344-A1 | USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0410358-B1 | AROMATIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| US-5216153-A | Therapy and prophylaxis for skin, autoimmune and rheumatic diseases | HOFFMANN-LA ROCHE INC. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5128470-A | Aantiinflammatory, antiallergens | HOFFMANN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0410358-A1 | Aromatic carboxylic acid amides, their preparation and their use as medicines | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039272-A1 | Compounds activating pharmacological effect of retinoids | RXRA, RXRG, RXRB | RARA 6/4885RARB 5/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.